Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56


In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice.

Conforti P, Mas Monteys A, Zuccato C, Buckley NJ, Davidson B, Cattaneo E.

Gene Ther. 2013 Jun;20(6):678-85. doi: 10.1038/gt.2012.84. Epub 2012 Nov 15.


Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models.

Conforti P, Zuccato C, Gaudenzi G, Ieraci A, Camnasio S, Buckley NJ, Mutti C, Cotelli F, Contini A, Cattaneo E.

J Neurochem. 2013 Oct;127(1):22-35. doi: 10.1111/jnc.12348. Epub 2013 Jul 19.


Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease.

Zuccato C, Belyaev N, Conforti P, Ooi L, Tartari M, Papadimou E, MacDonald M, Fossale E, Zeitlin S, Buckley N, Cattaneo E.

J Neurosci. 2007 Jun 27;27(26):6972-83.


Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington's disease.

Soldati C, Bithell A, Conforti P, Cattaneo E, Buckley NJ.

J Neurochem. 2011 Feb;116(3):415-25. doi: 10.1111/j.1471-4159.2010.07122.x. Epub 2010 Dec 13.


Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.

Bithell A, Johnson R, Buckley NJ.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270. Review.


High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes.

Charbord J, Poydenot P, Bonnefond C, Feyeux M, Casagrande F, Brinon B, Francelle L, Aurégan G, Guillermier M, Cailleret M, Viegas P, Nicoleau C, Martinat C, Brouillet E, Cattaneo E, Peschanski M, Lechuga M, Perrier AL.

Stem Cells. 2013 Sep;31(9):1816-28. doi: 10.1002/stem.1430.


Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington's disease.

Soldati C, Bithell A, Johnston C, Wong KY, Stanton LW, Buckley NJ.

J Neurochem. 2013 Feb;124(3):418-30. doi: 10.1111/jnc.12090.


Analysis of the repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy of non-neuronal genes in peripheral lymphocytes from patients with Huntington's disease.

Marullo M, Valenza M, Mariotti C, Di Donato S, Cattaneo E, Zuccato C.

Brain Pathol. 2010 Jan;20(1):96-105. doi: 10.1111/j.1750-3639.2008.00249.x. Epub 2008 Dec 23.


Regulation of RE1 protein silencing transcription factor (REST) expression by HIP1 protein interactor (HIPPI).

Datta M, Bhattacharyya NP.

J Biol Chem. 2011 Sep 30;286(39):33759-69. doi: 10.1074/jbc.M111.265173. Epub 2011 Aug 6.


AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.

Alto LT, Chen X, Ruhn KA, Treviño I, Tansey MG.

PLoS One. 2014 May 13;9(5):e96544. doi: 10.1371/journal.pone.0096544. eCollection 2014.


Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.

Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR.

J Neurosci. 2007 Oct 24;27(43):11758-68.


Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.

Samadi P, Boutet A, Rymar VV, Rawal K, Maheux J, Kvann JC, Tomaszewski M, Beaubien F, Cloutier JF, Levesque D, Sadikot AF.

Genes Brain Behav. 2013 Feb;12(1):108-24. doi: 10.1111/j.1601-183X.2012.00858.x. Epub 2012 Nov 21.


Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.

Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín-Ibañez R, Muñoz MT, Mengod G, Ernfors P, Alberch J.

J Neurosci. 2004 Sep 1;24(35):7727-39.


SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease.

Leone S, Mutti C, Kazantsev A, Sturlese M, Moro S, Cattaneo E, Rigamonti D, Contini A.

Bioorg Med Chem. 2008 May 15;16(10):5695-703. doi: 10.1016/j.bmc.2008.03.067. Epub 2008 Mar 30.


Gene dysregulation in Huntington's disease: REST, microRNAs and beyond.

Johnson R, Buckley NJ.

Neuromolecular Med. 2009;11(3):183-99. doi: 10.1007/s12017-009-8063-4. Epub 2009 May 21.


Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.

Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E.

Mol Cell Neurosci. 2008 Sep;39(1):1-7. doi: 10.1016/j.mcn.2008.04.012. Epub 2008 May 10.


Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease.

Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, Simmons DA.

J Neurosci. 2007 Apr 18;27(16):4424-34.


Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.

Ebert AD, Barber AE, Heins BM, Svendsen CN.

Exp Neurol. 2010 Jul;224(1):155-62. doi: 10.1016/j.expneurol.2010.03.005. Epub 2010 Mar 19.


Cell type-specific regulation of RE-1 silencing transcription factor (REST) target genes.

Hohl M, Thiel G.

Eur J Neurosci. 2005 Nov;22(9):2216-30.


Supplemental Content

Support Center